Intercept Pharma (ICPT): Symphony Data Shows Ocaliva Continuing To Grow - Wedbush

November 25, 2016 7:03 AM EST
Get Alerts ICPT Hot Sheet
Price: $101.73 -3.88%

Rating Summary:
    17 Buy, 3 Hold, 5 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 20 | Down: 30 | New: 24
Trade ICPT Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) after weekly Symphony Health sales and volume estimates for Ocaliva were slightly under $1.1MM and just over 190 pack units (both up ~11% w/w).

New prescriptions accounted for ~54% of total sales and ~46% were from refill prescriptions. Ocaliva was granted accelerated approval by FDA on May 27, 2016 and launched by Intercept early in June for the treatment of primary biliary cholangitis (PBC). The company disclosed that annual list price (ALP) is $69,350/patient/year or monthly wholesale acquisition cost (WAC) of $5,700 for a 30- day prescription.

No change to the 12-month price target of $224, calculated using a sum of parts for each treatment/disease with each calculated using a 30% annual discount from peak annual sales projection then applying a 1-10x multiple depending on stage of development.

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $114.28 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Definitive Agreement, Liana Moussatos

Add Your Comment